S1 Episode 4: How Can We Assess Cognitive Functioning in Patients With Schizophrenia? And What Can We Do About It?

Drs John Kane and Philip D. Harvey discuss how physicians can assess cognitive functioning in patients with schizophrenia and how to utilize rehabilitation and technology to address it.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969529). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://www.medscape.com/resource/schizophrenia

Schizophrenia Practice Essentials https://emedicine.medscape.com/article/288259-overview

The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.163.3.426

Comprehensive Review of the Research Employing the Schizophrenia Cognition Rating Scale (SCoRS) https://www.sciencedirect.com/science/article/pii/S0920996419302178

Using a Meta-cognitive Wisconsin Card Sorting Test to Measure Introspective Accuracy and Biases in Schizophrenia and Bipolar Disorder https://www.sciencedirect.com/science/article/abs/pii/S0022395621003903

Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256669/

Brain HQ https://www.brainhq.com/

Training Engagement, Baseline Cognitive Functioning, and Cognitive Gains With Computerized Cognitive Training: A Cross-Diagnostic Study https://europepmc.org/article/pmc/pmc6889599

Efficacy and Safety of the Novel Glycine Transporter Inhibitor BI 425809 Once Daily in Patients With Schizophrenia: A Double-Blind, Randomised, Placebo-Controlled Phase 2 Study https://linkinghub.elsevier.com/retrieve/pii/S2215-0366(20)30513-7

A Study to Test Long-term Safety of BI 425809 in People With Schizophrenia Who Took Part in a Previous CONNEX Study https://clinicaltrials.gov/ct2/show/NCT05211947

Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients With Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105423/

Karunatx.com. KarXT https://karunatx.com/pipeline-programs/karxt/

F46. The Potential of M1 Agonists to Treat Cognitive Impairment: Evidence From a Phase 2 Study of KarXT in Schizophrenia (EMERGENT-1) https://pmg.joynadmin.org/documents/1007/6247485871767404791c9d14.pdf

Cognitive Training and Supported Employment for Persons With Severe Mental Illness: One-Year Results From a Randomized Controlled Trial https://academic.oup.com/schizophreniabulletin/article/31/4/898/1877695

Long-Acting Antipsychotic Therapies for Patients With Schizophrenia https://reference.medscape.com/recap/949130

Why Treating Early, Treating Well, and Treating for Life Is Important in Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991981/

Progressive Brain Change in Schizophrenia: A Prospective Longitudinal Study of First-Episode Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496792/

P515. Genomic Analyses of Schizophrenia and Bipolar Disorder Patients With Very Poor Outcomes https://www.researchgate.net/publication/360255195_P515_Genomic_Analyses_of_Schizophrenia_and_Bipolar_Disorder_Patients_With_Very_Poor_Outcomes

Challenges in Assessment of Daytime Sleepiness in Cognitively Impaired Populations Can Be Bypassed Through Use of Ecological Momentary Assessment https://scholarship.miami.edu/esploro/outputs/report/Challenges-in-Assessment-of-Daytime-Sleepiness/991031600661502976

Evidence for Avolition in Bipolar Disorder? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141033/